Management of syphilis in the HIV-infected patient: Facts and controversies

Clinics in Dermatology

Volumn 28, Issue 5, 2010, Pages 539-545

  Farhi, David ^a   Dupin, Nicolas ^b  

^a Hôpital Cochin APHP Université Paris V ^*  (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIRETROVIRUS AGENT; BENZATHINE PENICILLIN; LIPOPROTEIN; PROBENECID;

ARTICLE; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; LONG TERM CARE; LUMBAR PUNCTURE; LYMPHOCYTE COUNT; MIXED INFECTION; NEUROSYPHILIS; PANDEMIC; PREVALENCE; PRIORITY JOURNAL; SAMPLE SIZE; SEROLOGY; SEXUAL BEHAVIOR; SINGLE DRUG DOSE; SYPHILIS; TREATMENT RESPONSE; TREPONEMA PALLIDUM; UNSAFE SEX; VIRUS LOAD; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL PUNCTURE; SYPHILIS; UNSAFE SEX;

EID: 77955928556     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2010.03.012     Document Type: Article

References (69)

1. Doherty L., Fenton K.A., Jones J., et al. Syphilis: old problem, new strategy. BMJ 2002, 325:153-156.
2. Farhi D., Dupin N. Infections sexuellement transmissibles: syphilis, uréthrites et condylomes 2008, Masson, Paris. D. Bessis (Ed.).
3. Lautenschlager S. Cutaneous manifestations of syphilis: recognition and management. Am J Clin Dermatol 2006, 7:291-304.
4. Zetola N.M., Klausner J.D. Syphilis and HIV infection: an update. Clin Infect Dis 2007, 44:1222-1228.
5. French P. Syphilis. BMJ 2007, 334:143-147.
6. Dupin N., Jdid R., N'Guyen Y.T., et al. Syphilis and gonorrhoea in Paris: the return. AIDS 2001, 15:814-815.
7. Chen S.Y., Gibson S., Katz M.H., et al. Continuing increases in sexual risk behavior and sexually transmitted diseases among men who have sex with men: San Francisco, Calif, 1999-2001, USA. Am J Public Health 2002, 92:1387-1388.
8. Hourihan M., Wheeler H., Houghton R., et al. Lessons from the syphilis outbreak in homosexual men in east London. Sex Transm Infect 2004, 80:509-511.
9. Wasserheit J.N. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992, 19:61-77.
10. Golden M.R., Marra C.M., Holmes K.K. Update on syphilis: resurgence of an old problem. JAMA 2003, 290:1510-1514.
11. Workowski K.A., Berman S.M. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55:1-94.
12. Dumortier C., Alcaraz I., Tone A., et al. Non-cutaneous manifestations of secondary syphilis. Ann Dermatol Venereol 2008, 135:451-458.
13. Health Protection Agency Mapping the issues: HIV and other sexually transmitted infections in the United Kingdom Available at:, Accessed Feb 8, 2008. http://www.hpa.org.ul//web/HPAwebFile/HPAweb_C/1194947365435.
14. Scheer S., Chu P.L., Klausner J.D., et al. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet 2001, 357:432-435.
15. Belongia E.A., Danila R.N., Angamuthu V., et al. A population-based study of sexually transmitted disease incidence and risk factors in human immunodeficiency virus-infected people. Sex Transm Dis 1997, 24:251-256.
16. Chesson H.W., Heffelfinger J.D., Voigt R.F., et al. Estimates of primary and secondary syphilis rates in persons with HIV in the United States, 2002. Sex Transm Dis 2005, 32:265-269.
17. Blocker M.E., Levine W.C., St Louis M.E. HIV prevalence in patients with syphilis, United States. Sex Transm Dis 2000, 27:53-59.
18. Quinn T.C., Cannon R.O., Glasser D., et al. The association of syphilis with risk of human immunodeficiency virus infection in patients attending sexually transmitted disease clinics. Arch Intern Med 1990, 150:1297-1302.
19. Fleming D.T., Wasserheit J.N. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999, 75:3-17.
20. Rottingen J.A., Cameron D.W., Garnett G.P. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?. Sex Transm Dis 2001, 28:579-597.
21. Cameron D.W., Simonsen J.N., D'Costa L.J., et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989, 2:403-407.
22. Darrow W.W., Echenberg D.F., Jaffe H.W., et al. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am J Public Health 1987, 77:479-483.
23. Gadkari D.A., Quinn T.C., Gangakhedkar R.R., et al. HIV-1 DNA shedding in genital ulcers and its associated risk factors in Pune, India. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:277-281.
24. Lafond R.E., Lukehart S.A. Biological basis for syphilis. Clin Microbiol Rev 2006, 19:29-49.
25. Theus S.A., Harrich D.A., Gaynor R., et al. Treponema pallidum, lipoproteins, and synthetic lipoprotein analogues induce human immunodeficiency virus type 1 gene expression in monocytes via NF-kappaB activation. J Infect Dis 1998, 177:941-950.
26. Sellati T.J., Wilkinson D.A., Sheffield J.S., et al. Virulent Treponema pallidum, lipoprotein, and synthetic lipopeptides induce CCR5 on human monocytes and enhance their susceptibility to infection by human immunodeficiency virus type 1. J Infect Dis 2000, 181:283-293.
27. Buchacz K., Patel P., Taylor M., et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS 2004, 18:2075-2079.
28. Kofoed K., Gerstoft J., Mathiesen L.R., et al. Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis 2006, 33:143-148.
29. Flores J.L. Syphilis. A tale of twisted treponemes. West J Med 1995, 163:552-559.
30. Ghanem K.G., Moore R.D., Rompalo A.M., et al. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis 2008, 47:258-265.
31. Birnbaum NR, Goldschmidt RH, Buffett WO. Resolving the common clinical dilemmas of syphilis. Am Fam Phys 1999;59:2233-40, 45-6.
32. Johns D.R., Tierney M., Felsenstein D. Alteration in the natural history of neurosyphilis by concurrent infection with the human immunodeficiency virus. N Engl J Med 1987, 316:1569-1572.
33. Berry C.D., Hooton T.M., Collier A.C., et al. Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection. N Engl J Med 1987, 316:1587-1589.
34. Katz D.A., Berger J.R., Duncan R.C. Neurosyphilis. A comparative study of the effects of infection with human immunodeficiency virus. Arch Neurol 1993, 50:243-249.
35. Gourevitch M.N., Selwyn P.A., Davenny K., et al. Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Ann Intern Med 1993, 118:350-355.
36. Hutchinson C.M., Hook E.W., Shepherd M., et al. Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection. Ann Intern Med 1994, 121:94-100.
37. Rompalo A.M., Joesoef M.R., O'Donnell J.A., et al. Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Sex Transm Dis 2001, 28:158-165.
38. Rolfs R.T., Joesoef M.R., Hendershot E.F., et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997, 337:307-314.
39. Chan D.J. Syphilis and HIV co-infection: when is lumbar puncture indicated?. Curr HIV Res 2005, 3:95-98.
40. Hook E.W., Marra C.M. Acquired syphilis in adults. N Engl J Med 1992, 326:1060-1069.
41. Berger J.R. Neurosyphilis in human immunodeficiency virus type 1-seropositive individuals. A prospective study. Arch Neurol 1991, 48:700-702.
42. Katz D.A., Berger J.R. Neurosyphilis in acquired immunodeficiency syndrome. Arch Neurol 1989, 46:895-898.
43. Holtom P.D., Larsen R.A., Leal M.E., et al. Prevalence of neurosyphilis in human immunodeficiency virus-infected patients with latent syphilis. Am J Med 1992, 93:9-12.
44. Lukehart S.A., Hook E.W., Baker-Zander S.A., et al. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med 1988, 109:855-862.
45. Marra C.M., Maxwell C.L., Smith S.L., et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004, 189:369-376.
46. Marra C.M., Maxwell C.L., Tantalo L., et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter?. Clin Infect Dis 2004, 38:1001-1006.
47. Ghanem K.G., Moore R.D., Rompalo A.M., et al. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 2008, 22:1145-1151.
48. Goh B.T., van Voorst Vader P.C. European guideline for the management of syphilis. Int J STD AIDS 2001, 12(suppl 3):14-26.
49. British Association for Sexual Health and HIV UK national guidelines on the management of syphilis 2008 2008, Clinical Effectiveness Group, Available at:, Accessed Feb 8, 2008. http://www.bashh.org/documents/1771.
50. Goh B.T. Syphilis in adults. Sex Transm Infect 2005, 81:448-452.
51. Marshall D.W., Brey R.L., Butzin C.A., et al. CSF changes in a longitudinal study of 124 neurologically normal HIV-1-infected U.S. Air Force personnel. J Acquir Immune Defic Syndr 1991, 4:777-781.
52. Collier A.C., Marra C., Coombs R.W., et al. Central nervous system manifestations in human immunodeficiency virus infection without AIDS. J Acquir Immune Defic Syndr 1992, 5:229-241.
53. Halperin L.S. Neuroretinitis due to seronegative syphilis associated with human immunodeficiency virus. J Clin Neuroophthalmol 1992, 12:171-172.
54. Hicks C.B., Benson P.M., Lupton G.P., et al. Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma. Ann Intern Med 1987, 107:492-495.
55. Terry P.M., Page M.L., Goldmeier D. Are serological tests of value in diagnosing and monitoring response to treatment of syphilis in patients infected with human immunodeficiency virus?. Genitourin Med 1988, 64:219-222.
56. Rompalo A.M., Cannon R.O., Quinn T.C., et al. Association of biologic false-positive reactions for syphilis with human immunodeficiency virus infection. J Infect Dis 1992, 165:1124-1126.
57. Augenbraun M.H., DeHovitz J.A., Feldman J., et al. Biological false-positive syphilis test results for women infected with human immunodeficiency virus. Clin Infect Dis 1994, 19:1040-1044.
58. Jurado R.L., Campbell J., Martin P.D. Prozone phenomenon in secondary syphilis. Has its time arrived. Arch Intern Med 1993, 153:2496-2498.
59. Rusnak J.M., Butzin C., McGlasson D., et al. False-positive rapid plasma reagin tests in human immunodeficiency virus infection and relationship to anti-cardiolipin antibody and serum immunoglobulin levels. J Infect Dis 1994, 169:1356-1359.
60. Goeman J., Kivuvu M., Nzila N., et al. Similar serological response to conventional therapy for syphilis among HIV-positive and HIV-negative women. Genitourin Med 1995, 71:275-279.
61. Browning D.J. Posterior segment manifestations of active ocular syphilis, their response to a neurosyphilis regimen of penicillin therapy, and the influence of human immunodeficiency virus status on response. Ophthalmology 2000, 107:2015-2023.
62. Long C.M., Klausner J.D., Leon S., et al. Syphilis treatment and HIV infection in a population-based study of persons at high risk for sexually transmitted disease/HIV infection in Lima, Peru. Sex Transm Dis 2006, 33:151-155.
63. Ghanem K.G., Erbelding E.J., Wiener Z.S., et al. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect 2007, 83:97-101.
64. Telzak E.E., Greenberg M.S., Harrison J., et al. Syphilis treatment response in HIV-infected individuals. AIDS 1991, 5:591-595.
65. Yinnon A.M., Coury-Doniger P., Polito R., et al. Serologic response to treatment of syphilis in patients with HIV infection. Arch Intern Med 1996, 156:321-325.
66. Malone J.L., Wallace M.R., Hendrick B.B., et al. Syphilis and neurosyphilis in a human immunodeficiency virus type-1 seropositive population: evidence for frequent serologic relapse after therapy. Am J Med 1995, 99:55-63.
67. Walter T., Lebouche B., Miailhes P., et al. Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. Clin Infect Dis 2006, 43:787-790.
68. Parkes R., Renton A., Meheus A., et al. Review of current evidence and comparison of guidelines for effective syphilis treatment in Europe. Int J STD AIDS 2004, 15:73-88.
69. Cohen C.E., Winston A., Asboe D., et al. Increasing detection of asymptomatic syphilis in HIV patients. Sex Transm Infect 2005, 81:217-219.